Clinical Trial

Secondhand Tobacco Smoke and Cardiovascular Disease

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-01-14; most recent amendment 2025-07-21.
Status change: Not Yet Recruiting → Recruiting 2021-04-02
Trial Details
NCT Number NCT04715568
Lead Sponsor University of California, San Francisco
Collaborators: Flight Attendant Medical Research Institute
Conditions Cardiovascular Diseases, Hypertension
Enrollment 100 participants
Start Date 2021-03-30
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-23